Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

APCCC 2022 | Survivorship in metastatic prostate cancer

Silke Gillessen • 17 May 2022
APCCC 2022
Genitourinary Cancer Prostate Cancer

Silke Gillessen, MD, PhD, University of Lugano, Lugano, Switzerland and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, discusses the importance of patients in choosing a treatment for metastatic prostate cancer. Prof. Gillessen also discusses the use of geriatric assessment in clinical practice and the importance of biological age in the management of metastatic prostate cancer. This interview took place at the APCCC 2022 conference, held in Lugano, Switzerland.

More from Silke Gillessen

2:30
PARP inhibitors plus novel endocrine agents for patients with metastatic prostate cancer
Silke Gillessen • 18 Feb 2023
1:23
The role of immune checkpoint inhibitors in mCRPC
Silke Gillessen • 18 Feb 2023
2:12
Criteria for treatment selection for patients with CRPC
Silke Gillessen • 18 Feb 2023
2:43
Treatment sequencing and combinations for prostate cancer
Silke Gillessen • 18 Feb 2023

Related Videos

2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals